Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions

Next Previous
Trial Profile

A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erdafitinib (Primary) ; Gemcitabine; Metformin; Midazolam; Mitomycin
  • Indications Bladder cancer; Neuroendocrine carcinoma; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms THOR-2
  • Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

  • 09 Apr 2025 Status changed from active, no longer recruiting to completed.
  • 31 Jan 2025 Planned End Date changed from 1 Mar 2025 to 3 Mar 2025.
  • 21 May 2024 Planned primary completion date changed from 29 Mar 2024 to 12 Jul 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top